NRCAM and thyroid cancer: Proteolytic cleavage of NrCAM at the cell surface of K1 cells results in the release of the extracellular domain of NrCAM, which activates EGFR signaling when presented in the culture medium to thyroid cancer IHH4 cells, suggesting that it binds in trans to EGFR at the cell surface [88].